Furthermore, the most prevalent adverse events with IL-17/23 inhibitors and TNF-α blockers in meta-analyses, including injection site reaction, infections, nasopharyngitis, and headache, were not reported in DCS subjects in our study [94, 95]. This evidence concerns the gene TNF and Headache.